NASDAQ:NVCR NovoCure - NVCR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. $57.17 +0.36 (+0.63%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$56.06▼$57.6450-Day Range$56.44▼$95.0952-Week Range$56.06▼$120.03Volume561,258 shsAverage Volume1.09 million shsMarket Capitalization$6.03 billionP/E RatioN/ADividend YieldN/APrice Target$87.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability NovoCure MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside52.8% Upside$87.33 Price TargetShort InterestBearish8.26% of Shares Sold ShortDividend StrengthN/ASustainability-1.15Upright™ Environmental ScoreNews Sentiment0.18Based on 5 Articles This WeekInsider TradingSelling Shares$24.67 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.65) to ($1.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.98 out of 5 starsMedical Sector648th out of 989 stocksSurgical & Medical Instruments Industry64th out of 99 stocks 3.0 Analyst's Opinion Consensus RatingNovoCure has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 2 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $87.33, NovoCure has a forecasted upside of 52.8% from its current price of $57.17.Amount of Analyst CoverageNovoCure has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.26% of the outstanding shares of NovoCure have been sold short.Short Interest Ratio / Days to CoverNovoCure has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in NovoCure has recently increased by 3.44%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNovoCure does not currently pay a dividend.Dividend GrowthNovoCure does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNovoCure has received a 68.17% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Brain cancer medication", and "Cabozantinib" products. See details.Environmental SustainabilityThe Environmental Impact score for NovoCure is -1.15. Previous Next 2.9 News and Social Media Coverage News SentimentNovoCure has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for NovoCure this week, compared to 3 articles on an average week.Search Interest28 people have searched for NVCR on MarketBeat in the last 30 days. This is an increase of 65% compared to the previous 30 days.MarketBeat Follows16 people have added NovoCure to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NovoCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,674,511.00 in company stock.Percentage Held by InsidersOnly 6.22% of the stock of NovoCure is held by insiders.Percentage Held by Institutions78.42% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for NovoCure are expected to decrease in the coming year, from ($1.65) to ($1.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovoCure is -64.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovoCure is -64.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovoCure has a P/B Ratio of 13.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NovoCure (NASDAQ:NVCR) StockNovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.Read More Receive NVCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter. Email Address NVCR Stock News HeadlinesMarch 20, 2023 | americanbankingnews.comJPMorgan Chase & Co. Reaffirms "Underweight" Rating for NovoCure (NASDAQ:NVCR)March 16, 2023 | finance.yahoo.comInstitutional investors may adopt severe steps after NovoCure Limited's (NASDAQ:NVCR) latest 7.3% drop adds to a year lossesMarch 24, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 1, 2023 | finance.yahoo.comNovocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in FranceFebruary 24, 2023 | finance.yahoo.comNovoCure Full Year 2022 Earnings: US$0.88 loss per share (vs US$0.56 loss in FY 2021)February 24, 2023 | finance.yahoo.comNovoCure Full Year 2022 Earnings: US$0.88 loss per share (vs US$0.56 loss in FY 2021)February 23, 2023 | finance.yahoo.comWhy NovoCure Stock Is Falling TodayFebruary 10, 2023 | finance.yahoo.comShould You Investigate NovoCure Limited (NASDAQ:NVCR) At US$87.50?March 24, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. January 19, 2023 | finance.yahoo.comNovocure Round-Trips Its Recent Breakout After Announcing A Series Of C-Suite ChangesJanuary 17, 2023 | finance.yahoo.comNovocure Has Fallen More Than 20% Over Seven Days — Why It Fell From GraceJanuary 6, 2023 | finance.yahoo.comWhy Novocure Stock Is Flying HighJanuary 5, 2023 | finance.yahoo.comNovocure Skyrockets 69% After Pulling Off A Once-In-Six-Years FeatJanuary 5, 2023 | finance.yahoo.comWhy Novocure Stock Is Skyrocketing TodayDecember 27, 2022 | finance.yahoo.comNovocure to Participate in 41st Annual J.P. Morgan Healthcare ConferenceNovember 30, 2022 | finance.yahoo.comIs NovoCure Limited (NASDAQ:NVCR) Worth US$74.7 Based On Its Intrinsic Value?November 26, 2022 | finance.yahoo.comNovocure Stock: Bull vs. BearNovember 15, 2022 | finance.yahoo.comNovocure Opens Office in Montreal to Expand and Support Growing Business in CanadaNovember 11, 2022 | finance.yahoo.comNovocure Secures CE Mark for New ArrayNovember 8, 2022 | finance.yahoo.com2 Potentially Explosive Stocks to Buy in NovemberNovember 4, 2022 | msn.comNovoCure's Return On Capital Employed InsightsOctober 27, 2022 | finance.yahoo.comNovoCure (NVCR) Reports Q3 Loss, Lags Revenue EstimatesOctober 27, 2022 | finance.yahoo.comNovocure (NVCR) Q3 2022 Earnings Call TranscriptOctober 25, 2022 | seekingalpha.comNovoCure downgraded at Piper Sandler despite positive Phase 3 readout aheadOctober 24, 2022 | finance.yahoo.comWhy Novocure Stock Is Sinking TodayOctober 23, 2022 | finance.yahoo.comNovoCure (NASDAQ:NVCR) shareholders have earned a 30% CAGR over the last five yearsOctober 13, 2022 | nasdaq.com3 Unstoppable Stocks You Can Buy Now for Less Than $100 - NasdaqSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NVCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter. Email Address NVCR Company Calendar Last Earnings2/23/2023Today3/24/2023Next Earnings (Estimated)4/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVCR CUSIPN/A CIK1645113 Webwww.novocure.com Phone441534756700FaxN/AEmployees1,320Year FoundedN/APrice Target and Rating Average Stock Price Forecast$87.33 High Stock Price Forecast$130.00 Low Stock Price Forecast$50.00 Forecasted Upside/Downside+53.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,530,000.00 Net Margins-17.20% Pretax Margin-15.22% Return on Equity-20.98% Return on Assets-7.91% Debt Debt-to-Equity Ratio1.28 Current Ratio7.00 Quick Ratio6.82 Sales & Book Value Annual Sales$537.84 million Price / Sales11.14 Cash FlowN/A Price / Cash FlowN/A Book Value$4.20 per share Price / Book13.53Miscellaneous Outstanding Shares105,460,000Free Float98,896,000Market Cap$5.99 billion OptionableOptionable Beta0.83 Key ExecutivesAsaf DanzigerChief Executive Officer & DirectorWilhelmus C. M. GroenhuysenChief Operating OfficerAshley CordovaChief Financial OfficerMoshe GiladiChief Science OfficerPiet HinoulSenior Vice President & Head-MedicalKey CompetitorsGlobus MedicalNYSE:GMEDStevanato GroupNYSE:STVNInspire Medical SystemsNYSE:INSPIntegra LifeSciencesNASDAQ:IARTShockwave MedicalNASDAQ:SWAVView All CompetitorsInsiders & InstitutionsNordwand Advisors LLCBought 1,515,000 shares on 3/7/2023Ownership: 1.437%Rockefeller Capital Management L.P.Sold 7,846 shares on 3/6/2023Ownership: 0.001%Frank X LeonardSold 2,059 sharesTotal: $159,860.76 ($77.64/share)Wilhelmus Cm GroenhuysenSold 2,164 sharesTotal: $165,243.04 ($76.36/share)Ashley CordovaSold 2,198 sharesTotal: $167,839.28 ($76.36/share)View All Insider TransactionsView All Institutional Transactions NVCR Stock - Frequently Asked Questions Should I buy or sell NovoCure stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVCR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCR, but not buy additional shares or sell existing shares. View NVCR analyst ratings or view top-rated stocks. What is NovoCure's stock price forecast for 2023? 6 brokers have issued twelve-month price objectives for NovoCure's shares. Their NVCR share price forecasts range from $50.00 to $130.00. On average, they anticipate the company's share price to reach $87.33 in the next year. This suggests a possible upside of 54.3% from the stock's current price. View analysts price targets for NVCR or view top-rated stocks among Wall Street analysts. How have NVCR shares performed in 2023? NovoCure's stock was trading at $73.35 at the start of the year. Since then, NVCR shares have decreased by 22.8% and is now trading at $56.60. View the best growth stocks for 2023 here. When is NovoCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023. View our NVCR earnings forecast. How were NovoCure's earnings last quarter? NovoCure Limited (NASDAQ:NVCR) announced its earnings results on Thursday, February, 23rd. The medical equipment provider reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.04. The medical equipment provider had revenue of $128.43 million for the quarter, compared to the consensus estimate of $127.20 million. NovoCure had a negative trailing twelve-month return on equity of 20.98% and a negative net margin of 17.20%. The business's quarterly revenue was down 3.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.25) EPS. What ETFs hold NovoCure's stock? ETFs with the largest weight of NovoCure (NASDAQ:NVCR) stock in their portfolio include BlueStar Israel Technology ETF (ITEQ), Principal Healthcare Innovators ETF (BTEC), VanEck Israel ETF (ISRA), First Trust Indxx Medical Devices ETF (MDEV), Strategas Global Policy Opportunities ETF (SAGP), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Health Care Equipment ETF (XHE) and iShares Biotechnology ETF (IBB). What guidance has NovoCure issued on next quarter's earnings? NovoCure issued an update on its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $128.40 million-$128.40 million, compared to the consensus revenue estimate of $129.14 million. What is Asaf Danziger's approval rating as NovoCure's CEO? 17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees. What other stocks do shareholders of NovoCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy Partners (VNOM), Roku (ROKU), Salesforce (CRM) and Block (SQ). What is NovoCure's stock symbol? NovoCure trades on the NASDAQ under the ticker symbol "NVCR." Who are NovoCure's major shareholders? NovoCure's stock is owned by a number of retail and institutional investors. Top institutional investors include Nordwand Advisors LLC (8.68%), Baillie Gifford & Co. (8.40%), Price T Rowe Associates Inc. MD (2.07%), Nordwand Advisors LLC (1.44%), Geode Capital Management LLC (1.29%) and Norges Bank (0.93%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle. View institutional ownership trends. How do I buy shares of NovoCure? Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NovoCure's stock price today? One share of NVCR stock can currently be purchased for approximately $56.60. How much money does NovoCure make? NovoCure (NASDAQ:NVCR) has a market capitalization of $5.97 billion and generates $537.84 million in revenue each year. The medical equipment provider earns $-92,530,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. How many employees does NovoCure have? The company employs 1,320 workers across the globe. How can I contact NovoCure? NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The official website for the company is www.novocure.com. The medical equipment provider can be reached via phone at 441534756700 or via email at investorinfo@novocure.com. This page (NASDAQ:NVCR) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.